Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting

BACKGROUND: Omalizumab is a monoclonal antibody, indicated for the treatment of severe allergic asthma. In Europe, there have been concerns about the cardiovascular safety of omalizumab. The objective of this study was to analyze the association between omalizumab and arterial thrombotic events in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Ayad K, Hartzema, Abraham G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363016/
https://www.ncbi.nlm.nih.gov/pubmed/22690127
http://dx.doi.org/10.2147/JAA.S29811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363016/
https://www.ncbi.nlm.nih.gov/pubmed/22690127
http://dx.doi.org/10.2147/JAA.S29811

Ejemplares similares